Filtered By:
Condition: Diabetes Type 2
Drug: Insulin
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 514 results found since Jan 2013.
What is type 2 diabetes?
Type 2 diabetes mellitus (T2DM) is a common metabolic disorder characterized by chronic hyperglycaemia. It is associated with reduced life expectancy owing to a greater risk of heart disease, stroke, peripheral neuropathy, renal disease, blindness and amputation. The best-known predictors of increased diabetes risk are elevated fasting plasma glucose, elevated 1- and 2-hour plasma glucose after an oral glucose tolerance test, obesity and evidence of impaired insulin action. However, the mechanisms by which people with impaired fasting glucose and/or abnormal glucose tolerance ‘progress’ to overt T2DM are not completely understood.
Source: Medicine - November 29, 2018 Category: Internal Medicine Authors: Maria Daniela Hurtado, Adrian Vella Tags: Diabetes: basic facts Source Type: research
Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts
ConclusionWe present evidence describing the prevalence of T2DM in patients with SCD both in a commercially-insured population and from an institution-based clinical cohort. These findings were similar to a general African American population with an increasing trend in T2DM over recent years. These trends support the routine screening for T2DM in patients with SCD, especially those of older age and with presence of comorbid hypertension and/or dyslipidemia.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Zhou, J., Han, J., Nutescu, E. A., Galanter, W., Walton, S. M., Gordeuk, V. R., Saraf, S. L., Srisuwananukorn, A., Calip, G. S. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster III Source Type: research
Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification
ConclusionsThis study confirms the high prevalence of CKD in patients with multiple comorbidities: T2D and CVD. It also provides estimates of the prevalence of CKD categories based on KDIGO 2012 classification for US adults with T2D.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - November 3, 2018 Category: Endocrinology Source Type: research
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Abstract
Patients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the new class of glucose-lowering medications that increase urinary glucose excretion, thus improving glycemic control, independent of insulin. The recently p...
Source: Indian Heart J - November 1, 2018 Category: Cardiology Authors: Pancholia AK Tags: Indian Heart J Source Type: research
IJERPH, Vol. 15, Pages 2368: Impact of Diabetes Mellitus on Human Erythrocytes: Atomic Force Microscopy and Spectral Investigations
el Masilamani
Diabetes mellitus (DM) is a common metabolic disease indicated by high sugar levels in the blood over a prolonged period. When left untreated, it can lead to long-term complications, such as cardiovascular disease, stroke, and diabetic retinopathy or foot ulcers. Approximately 415 million people (about 8.3% of the world’s population) had diabetes worldwide in 2015, with 90% of the cases classified as Type 2 DM, which is caused by insulin resistance that arises mostly from being overweight and from a lack of exercise. DM affects every part of the body, including the erythrocytes. The aim of t...
Source: International Journal of Environmental Research and Public Health - October 26, 2018 Category: Environmental Health Authors: Mohamad S. AlSalhi Sandhanasamy Devanesan Khalid E. AlZahrani Mashael AlShebly Fatima Al-Qahtani Karim Farhat Vadivel Masilamani Tags: Article Source Type: research
Bariatric surgery and diabetes remission: how far have we progressed?
This article will review the effectiveness of bariatric procedures on the remission and improvement of diabetes and its implicated mechanisms.
PMID: 30298760 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - October 12, 2018 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
The Case For Taking a Walk After You Eat
At the end of a long day, it’s tempting to dive into your social feeds or Netflix queue the minute you’ve finished eating. But back before screens bogarted all our free time, an after-dinner stroll was a popular activity and one associated with improved health and digestion. “Italians have been walking after meals for centuries,” says Loretta DiPietro, a professor of exercise science at George Washington University’s Milken Institute School of Public Health, “so it must be good.”
Research backs this up. One small study co-authored by DiPietro found that when older adults at risk fo...
Source: TIME: Health - September 26, 2018 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Exercise/Fitness Source Type: news
Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
ConclusionOur approach identifies salient T2D genetically anchored and physiologically informed pathways, and supports the use of genetics to deconstruct T2D heterogeneity. Classification of patients by these genetic pathways may offer a step toward genetically informed T2D patient management.
Source: PLoS Medicine - September 21, 2018 Category: Internal Medicine Authors: Miriam S. Udler Source Type: research
Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial
AbstractPurpose of ReviewThe DEVOTE study compared the cardiovascular safety of two basal insulins, degludec, and glargine U100 in patients with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD). In this review, we summarize the results of DEVOTE and provide a clinical perspective.Recent FindingsDEVOTE was a phase 3b, multicenter, international, treat-to-target, double-blind, event-driven trial. Patients with T2D> 50 years of age with prior CVD or> 60 years of age with CVD risk factors were randomly assigned to receive either degludec (n = 3818) or insulin glargine U100 (n = 3819) and ...
Source: Current Diabetes Reports - September 18, 2018 Category: Endocrinology Source Type: research
Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links.
Authors: Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP
Abstract
Metabolic syndrome (MetS), today a major global public health problem, is a cluster of clinical, metabolic, and biochemical abnormalities, such as central adiposity, hypertension, insulin resistance, and dyslipidemias. These MetS-related traits significantly increase the risk of type 2 diabetes mellitus, adverse cardiac events, stroke, and hepatic steatosis. The pathogenesis of MetS is multifactorial, with the interplay of environmental, nutritional, and genetic factors. Chronic low-grade inflammation together with visceral adipose tissue, adipocyte ...
Source: Hormones - September 2, 2018 Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research
Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
Authors: Raskin P, Cincotta AH
Abstract
An extended series of studies indicate that endogenous phase shifts in circadian neuronal input signaling to the biological clock system centered within the hypothalamic suprachiasmatic nucleus (SCN) facilitates shifts in metabolic status. In particular, a diminution of the circadian peak in dopaminergic input to the peri-SCN facilitates the onset of fattening, insulin resistance and glucose intolerance while reversal of low circadian peak dopaminergic activity to the peri-SCN via direct timed dopamine administration to this area normalizes the obese, insulin resistant, gluco...
Source: Expert Review of Endocrinology and Metabolism - August 2, 2018 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus.
CONCLUSION: This review discusses the strategies and future perspectives in the management of type 2 diabetes mellitus particularly antidiabetic agents which are helpful for the betterment of diabetic patients.
PMID: 30051787 [PubMed - as supplied by publisher]
Source: Current Drug Targets - July 27, 2018 Category: Drugs & Pharmacology Authors: Kaur P, Mittal A, Nayak SK, Vyas M, Mishra V, Khatik GL Tags: Curr Drug Targets Source Type: research
Guess What Google ’s Verily is Up to Now
Verily Life Sciences has formed yet another joint venture with a medtech company. This time Verily, once known as Google’s life sciences division, is teaming up with sleep-health specialist ResMed to tackle sleep apnea. The collaboration with ResMed expands the Mountain View, CA-based company’s presence into yet another healthcare segment.
ResMed executives declined to discuss specific details about the joint venture, noting it was still subject to regulatory approvals. However, ResMed CMO Carlos Nunez said the joint venture will operate as a completely separate entity from ResMed and Verily.
Nunez noted ResMed had ext...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news
Guess What Alphabet ’s Verily is Up to Now
Verily Life Sciences has formed yet another joint venture with a medtech company. This time Verily, once known as Google’s life sciences division, is teaming up with sleep-health specialist ResMed to tackle sleep apnea. The collaboration with ResMed expands the Mountain View, CA-based company’s presence into yet another healthcare segment.
ResMed executives declined to discuss specific details about the joint venture, noting it was still subject to regulatory approvals. However, ResMed CMO Carlos Nunez said the joint venture will operate as a completely separate entity from ResMed and Verily.
Nunez noted ResMed had ext...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news
